The Food and Drug Administration has approved Harliku (nitisinone) for the reduction of urine homogentisic acid in adult patients with alkaptonuria.

Alkaptonuria is a rare, autosomal recessive metabolic disorder arising from the deficiency of the enzyme homogentisate 1,2-dioxygenase, which disrupts the normal degradation of tyrosine. This ...

Alkaptonuria is an ultra-rare hereditary disorder of tyrosine and phenylalanine catabolism, and is commonly known as black urine disease due to the noticeable buildup of HGA. A slow-progressing ...

Cells contain helper molecules called transfer RNAs (tRNAs), which carry building blocks (amino acids) to make proteins.

Cycle Pharmaceuticals announced the launch of HARLIKU, the first and only FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adult patients with alkaptonuria (AKU). 1 AKU, also ...